DK3636764T3 - 3'-utr-sekvenser til rna-stabilisering - Google Patents
3'-utr-sekvenser til rna-stabilisering Download PDFInfo
- Publication number
- DK3636764T3 DK3636764T3 DK19198322.0T DK19198322T DK3636764T3 DK 3636764 T3 DK3636764 T3 DK 3636764T3 DK 19198322 T DK19198322 T DK 19198322T DK 3636764 T3 DK3636764 T3 DK 3636764T3
- Authority
- DK
- Denmark
- Prior art keywords
- utr sequences
- rna stabilization
- rna
- stabilization
- utr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B13/00—Details of tables or desks
- A47B13/02—Underframes
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B3/00—Folding or stowable tables
- A47B3/002—Folding or stowable tables with foldable underframe
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B33/00—Kitchen or dish-washing tables
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B43/00—Cabinets, racks or shelf units, characterised by features enabling folding of the cabinet or the like
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B77/00—Kitchen cabinets
- A47B77/02—General layout, e.g. relative arrangement of compartments, working surface or surfaces, supports for apparatus
- A47B77/022—Work tops
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B77/00—Kitchen cabinets
- A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
- A47B77/06—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts for incorporating sinks, with or without draining boards, splash-backs, or the like
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B77/00—Kitchen cabinets
- A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
- A47B77/08—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts for incorporating apparatus operated by power, including water power; for incorporating apparatus for cooking, cooling, or laundry purposes
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B77/00—Kitchen cabinets
- A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
- A47B77/16—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts by adaptation of compartments or drawers for receiving or holding foodstuffs; by provision of rotatable or extensible containers for foodstuffs
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B77/00—Kitchen cabinets
- A47B77/04—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts
- A47B77/18—Provision for particular uses of compartments or other parts ; Compartments moving up and down, revolving parts by special arrangements for accommodating removable containers
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B95/00—Fittings for furniture
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B95/00—Fittings for furniture
- A47B95/008—Suspension fittings for cabinets to be hung on walls
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47C—CHAIRS; SOFAS; BEDS
- A47C4/00—Foldable, collapsible or dismountable chairs
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47C—CHAIRS; SOFAS; BEDS
- A47C4/00—Foldable, collapsible or dismountable chairs
- A47C4/04—Folding chairs with inflexible seats
- A47C4/08—Folding chairs with inflexible seats having a frame made of wood or plastics
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47C—CHAIRS; SOFAS; BEDS
- A47C7/00—Parts, details, or accessories of chairs or stools
- A47C7/002—Chair or stool bases
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47C—CHAIRS; SOFAS; BEDS
- A47C7/00—Parts, details, or accessories of chairs or stools
- A47C7/002—Chair or stool bases
- A47C7/006—Chair or stool bases with castors
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47K—SANITARY EQUIPMENT NOT OTHERWISE PROVIDED FOR; TOILET ACCESSORIES
- A47K3/00—Baths; Douches; Appurtenances therefor
- A47K3/28—Showers or bathing douches
- A47K3/283—Fixed showers
- A47K3/284—Pre-fabricated shower cabinets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60B—VEHICLE WHEELS; CASTORS; AXLES FOR WHEELS OR CASTORS; INCREASING WHEEL ADHESION
- B60B33/00—Castors in general; Anti-clogging castors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04H—BUILDINGS OR LIKE STRUCTURES FOR PARTICULAR PURPOSES; SWIMMING OR SPLASH BATHS OR POOLS; MASTS; FENCING; TENTS OR CANOPIES, IN GENERAL
- E04H1/00—Buildings or groups of buildings for dwelling or office purposes; General layout, e.g. modular co-ordination or staggered storeys
- E04H1/12—Small buildings or other erections for limited occupation, erected in the open air or arranged in buildings, e.g. kiosks, waiting shelters for bus stops or for filling stations, roofs for railway platforms, watchmen's huts or dressing cubicles
- E04H1/125—Small buildings, arranged in other buildings
- E04H1/1266—Cubicles for dressing; Toilets
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
- F16C11/00—Pivots; Pivotal connections
- F16C11/04—Pivotal connections
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B3/00—Folding or stowable tables
- A47B3/002—Folding or stowable tables with foldable underframe
- A47B2003/006—Folding or stowable tables with foldable underframe having X/Y-crossed legs rotating around a central vertical axis
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
- A47B2200/00—General construction of tables or desks
- A47B2200/0011—Underframes
- A47B2200/0017—Nodal leg assembly for table
- A47B2200/0018—Nodal leg assembly for table in two parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/073180 WO2017059902A1 (en) | 2015-10-07 | 2015-10-07 | 3' utr sequences for stabilization of rna |
EP16778784.5A EP3337902B1 (en) | 2015-10-07 | 2016-10-05 | 3' utr sequences for stabilization of rna |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3636764T3 true DK3636764T3 (da) | 2021-03-22 |
Family
ID=54293227
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16778784T DK3337902T3 (da) | 2015-10-07 | 2016-10-05 | 3'-utr-sekvenser til stabilisering af rna |
DK19198322.0T DK3636764T3 (da) | 2015-10-07 | 2016-10-05 | 3'-utr-sekvenser til rna-stabilisering |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16778784T DK3337902T3 (da) | 2015-10-07 | 2016-10-05 | 3'-utr-sekvenser til stabilisering af rna |
Country Status (26)
Country | Link |
---|---|
US (2) | US11492628B2 (da) |
EP (3) | EP3636764B1 (da) |
JP (5) | JP7084302B2 (da) |
KR (2) | KR20220025195A (da) |
CN (1) | CN108291230B (da) |
AU (3) | AU2016335029B2 (da) |
BR (2) | BR122021025194B1 (da) |
CA (2) | CA3223575A1 (da) |
CY (2) | CY1122347T1 (da) |
DK (2) | DK3337902T3 (da) |
ES (2) | ES2753201T3 (da) |
HK (2) | HK1256701A1 (da) |
HR (2) | HRP20191907T1 (da) |
HU (2) | HUE046982T2 (da) |
IL (3) | IL293020A (da) |
LT (2) | LT3337902T (da) |
MX (2) | MX2018004160A (da) |
NZ (1) | NZ740946A (da) |
PL (2) | PL3636764T3 (da) |
PT (2) | PT3337902T (da) |
RS (2) | RS61684B1 (da) |
RU (1) | RU2720934C2 (da) |
SG (1) | SG10201912558YA (da) |
SI (2) | SI3636764T1 (da) |
WO (2) | WO2017059902A1 (da) |
ZA (1) | ZA201800835B (da) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
US11253601B2 (en) | 2016-07-11 | 2022-02-22 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
EP3668980A1 (en) * | 2017-08-15 | 2020-06-24 | Intellia Therapeutics, Inc. | Stabilized nucleic acids encoding messenger ribonucleic acid (mrna) |
WO2019154985A1 (en) | 2018-02-12 | 2019-08-15 | Biontech Rna Pharmaceuticals Gmbh | Treatment using cytokine encoding rna |
AU2019311233A1 (en) | 2018-07-24 | 2021-01-21 | BioNTech SE | IL2 agonists |
TW202043272A (zh) | 2019-01-14 | 2020-12-01 | 美商建南德克公司 | 使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法 |
AU2020218615A1 (en) | 2019-02-08 | 2021-09-30 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered T cells and cytokines |
AU2020242254A1 (en) | 2019-03-18 | 2020-09-24 | Biontech Cell & Gene Therapies Gmbh | Lnterleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells |
WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
EP4022068A1 (en) * | 2019-08-29 | 2022-07-06 | Universität Zürich | Minimal messenger rnas and uses thereof |
EP4048789A4 (en) * | 2019-10-22 | 2022-12-14 | The Regents of The University of California | MODULATION OF TRANSLATION OF GM CELLS USING NON-CODING SEQUENCE ELEMENTS |
CN116650628A (zh) | 2020-01-31 | 2023-08-29 | 基因泰克公司 | 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法 |
WO2021160346A1 (en) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
US20230405046A1 (en) | 2020-03-16 | 2023-12-21 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
KR102462990B1 (ko) * | 2020-03-17 | 2022-11-07 | 에이비온 주식회사 | 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물 |
MX2022012105A (es) | 2020-03-30 | 2022-10-18 | BioNTech SE | Composiciones de arn que se dirigen a claudina-18.2. |
WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
CN113521269A (zh) * | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
WO2021213945A1 (en) | 2020-04-22 | 2021-10-28 | Pfizer Inc. | Coronavirus vaccine |
EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
MX2023000618A (es) | 2020-07-17 | 2023-04-10 | Genentech Inc | Red neuronal basada en atencion para predecir union, presentacion e inmunogenicidad de peptidos. |
CA3187061A1 (en) | 2020-08-06 | 2022-02-10 | Karsten Beckmann | Binding agents for coronavirus s protein |
BR112023004247A2 (pt) | 2020-09-08 | 2023-04-11 | Genentech Inc | Kits de tubulação para formar uma mistura, sistemas para formar uma composição farmacêutica, métodos para transferir composições farmacêuticas e para fabricar uma composição farmacêutica e amortecedor de pulsação |
TW202227478A (zh) | 2020-09-15 | 2022-07-16 | 德商拜恩迪克公司 | 對細胞靶向遞送的藥劑及方法 |
EP4203997A1 (en) | 2020-10-26 | 2023-07-05 | Pécsi Tudományegyetem | Vaccine platform |
AU2021380005A1 (en) | 2020-11-11 | 2023-06-01 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2022106860A1 (en) | 2020-11-20 | 2022-05-27 | Pécsi Tudományegyetem | Recombinant peptides for use in therapy |
WO2022122689A1 (en) | 2020-12-09 | 2022-06-16 | BioNTech SE | Rna manufacturing |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
CN114717230A (zh) * | 2021-01-05 | 2022-07-08 | 麦塞拿治疗(香港)有限公司 | 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
WO2022223617A1 (en) | 2021-04-20 | 2022-10-27 | BioNTech SE | Virus vaccine |
WO2022228827A1 (en) | 2021-04-26 | 2022-11-03 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
WO2022235853A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Immunogen selection |
KR20240024806A (ko) | 2021-06-08 | 2024-02-26 | 비온테크 쎌 & 제네 테라피스 게엠베하 | 면역 작동자 세포의 활성화 및 표적화를 위한 물질 및 방법 |
WO2022270969A1 (ko) * | 2021-06-24 | 2022-12-29 | 한미약품 주식회사 | 비천연 5'-비번역 영역 및 3'-비번역 영역 및 그의 용도 |
IL309495A (en) | 2021-07-15 | 2024-02-01 | BioNTech SE | Agents encoding CLDN6 and CD3 binding elements for the treatment of CLDN6-positive cancer |
WO2023008793A1 (ko) * | 2021-07-27 | 2023-02-02 | 에스케이바이오사이언스(주) | 단백질 발현을 위한 mrna와 이를 위한 주형 |
CA3223943A1 (en) | 2021-07-29 | 2023-02-02 | Ugur Sahin | Compositions and methods for treatment of melanoma |
CA3227081A1 (en) | 2021-08-24 | 2023-03-02 | Irena RABE | In vitro transcription technologies |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057979A1 (en) * | 2021-10-07 | 2023-04-13 | Precision NanoSystems ULC | Rna vaccine lipid nanoparticles |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
TW202333803A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(一) |
WO2023061550A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023064612A2 (en) | 2021-10-15 | 2023-04-20 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
WO2023066496A1 (en) | 2021-10-21 | 2023-04-27 | BioNTech SE | Coronavirus vaccine |
EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4238577A3 (en) | 2021-10-22 | 2023-12-06 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
WO2023073190A1 (en) | 2021-10-28 | 2023-05-04 | BioNTech SE | Rna constructs and uses thereof |
WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
WO2023094713A2 (en) | 2021-11-29 | 2023-06-01 | BioNTech SE | Coronavirus vaccine |
WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023147092A2 (en) | 2022-01-28 | 2023-08-03 | BioNTech SE | Coronavirus vaccine |
WO2023214801A1 (ko) * | 2022-05-03 | 2023-11-09 | 단국대학교 산학협력단 | 단백질의 발현 수준 및 발현 위치 조절을 위한 utr 서열 및 이를 포함하는 mrna 서열 |
WO2023217987A1 (en) | 2022-05-12 | 2023-11-16 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
CN117660494A (zh) * | 2022-09-07 | 2024-03-08 | 远大赛威信生命科学(南京)有限公司 | 用于表达水痘-带状疱疹病毒抗原蛋白的mRNA及其用途 |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
WO2024074634A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074211A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
EP0846771A1 (en) | 1987-05-20 | 1998-06-10 | Novartis AG | Zea mays plants and transgenic zea mays plants regenerated from protoplasts or protoplast-derived cells |
RU2126047C1 (ru) * | 1987-05-29 | 1999-02-10 | Новартис Аг | Способ получения растений zea mays l., устойчивых к повреждениям, вызываемым насекомыми |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
ATE212670T1 (de) | 1990-06-18 | 2002-02-15 | Monsanto Technology Llc | Erhöhter stärkegehalt in pflanzen |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US6025542A (en) | 1992-12-28 | 2000-02-15 | Stichting Scheikundig Onderzoek In Nederland | Method for obtaining transgenic plants showing a modified fructan pattern |
NL9300646A (nl) * | 1992-12-28 | 1994-07-18 | Stichting Scheikundig Onderzoe | Werkwijze voor het verkrijgen van transgene planten welke een gemodificeerd fructaan-patroon vertonen. |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
DE69723434T2 (de) | 1996-04-26 | 2004-05-19 | Rijksuniversiteit Te Leiden | Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope |
DE69717661T2 (de) | 1996-09-13 | 2003-09-25 | Lipoxen Technologies Ltd | Liposomenzusammensetzung |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
WO1999024566A1 (en) | 1997-11-06 | 1999-05-20 | Roche Diagnostics Gmbh | Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
EP1117430A1 (en) | 1998-10-05 | 2001-07-25 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
WO2000050592A1 (en) * | 1999-02-24 | 2000-08-31 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
DE60041183D1 (de) | 1999-05-06 | 2009-02-05 | Univ Wake Forest | Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen |
AU4903101A (en) | 1999-11-30 | 2001-07-09 | Cornell Research Foundation Inc. | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
AU780064B2 (en) | 1999-12-28 | 2005-02-24 | Epimmune, Inc. | Optimized minigenes and peptides encoded thereby |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
AR044724A1 (es) | 2000-03-27 | 2005-10-05 | Syngenta Participations Ag | Promotores del virus de la rizadura amarilla del cestrum |
WO2001093902A2 (en) | 2000-06-07 | 2001-12-13 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
EP1392341B1 (de) | 2001-06-05 | 2005-03-30 | Curevac GmbH | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
IL160507A0 (en) | 2001-08-24 | 2004-07-25 | Advanced Cell Tech Inc | Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
KR20050016410A (ko) * | 2002-05-17 | 2005-02-21 | 베일러 칼리지 오브 메디신 | 도세탁셀 약제민감성 및 약제내성을 예측하는 특징적인유전자 발현 패턴 |
JP2005529187A (ja) | 2002-06-13 | 2005-09-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 同種抗原の特定方法、ならびに癌治療および移植へのその使用 |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
US7393653B2 (en) * | 2002-09-06 | 2008-07-01 | The Burnham Institute | Methods of modulating cell death based on the Bit1/AES regulatory pathway |
EP1556493B1 (en) | 2002-10-09 | 2010-03-17 | Cid Co., Ltd. | Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
JP5645340B2 (ja) | 2003-10-15 | 2014-12-24 | メディゲーネ アクチエンゲゼルシャフトMediGene AG | 活性成分を含有するカチオンリポソームの投与方法 |
DE602004030369D1 (de) | 2003-10-24 | 2011-01-13 | Immunaid Pty Ltd | Therapieverfahren |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
JP2008526764A (ja) | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 免疫応答の誘導におけるcd4+細胞の回避方法 |
GB0507997D0 (en) | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
DK1907424T3 (da) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | Humane monoklonale antistoffer mod programmeret dødsligand 1 (pd-l1) |
EP4174179A3 (en) | 2005-08-23 | 2023-09-27 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
DE602005026186D1 (de) * | 2005-12-12 | 2011-03-10 | Riyadh Sa | 3-nichttranslatierte hybridbereiche mit eignung zur effizienten proteinexpression in säugerzellen |
CA2651796A1 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
WO2007122369A2 (en) * | 2006-04-13 | 2007-11-01 | Oncomethylome Sciences Sa | Novel tumour suppressor |
WO2008085562A2 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
CA3045637A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
US20080220983A1 (en) * | 2007-03-08 | 2008-09-11 | Switchgear Genomics A California Corporation | Functional arrays for high throughput characterization of regulatory elements in untranslated regions of genes |
US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
ES2437327T3 (es) | 2007-06-18 | 2014-01-10 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor PD-1 humano de muerte programada |
RU2524431C2 (ru) | 2007-09-26 | 2014-07-27 | Интрексон Корпорейшн | Синтетические 5 utr (нетранслируемые области), экспрессионные векторы и способ повышения трансгенной экспрессии |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
EP2386557B1 (en) | 2008-03-24 | 2018-01-10 | 4SC Discovery GmbH | Novel substituted imidazoquinolines |
BRPI0910464B1 (pt) | 2008-04-17 | 2021-08-10 | Pds Biotechnology Corporation | Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica |
US10369204B2 (en) * | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
DK2459231T3 (da) | 2009-07-31 | 2016-09-05 | Ethris Gmbh | Rna med en kombination af umodificerede og modificerede nukleotider til proteinekspression |
WO2011075838A1 (en) | 2009-12-21 | 2011-06-30 | Audigen Inc. | Method of treating or preventing hearing loss |
EP3699266A1 (en) | 2010-05-14 | 2020-08-26 | The General Hospital Corporation | Neoantigen specific cytotoxic t cells for use in treating cancer |
ES2862955T3 (es) | 2010-10-01 | 2021-10-08 | Modernatx Inc | Acidos nucleicos manipulados y métodos de uso de los mismos |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
WO2013052523A1 (en) | 2011-10-03 | 2013-04-11 | modeRNA Therapeutics | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
RU2491343C1 (ru) * | 2011-12-23 | 2013-08-27 | Общество с ограниченной ответственностью "Биотехнологический центр трансгенеза в фарминдустрии "Трансгенфарм" | Генетические конструкции ltf3, ltf5, ltf7, ltf10, ltf11 для получения рекомбинантного лактоферрина человека (варианты) |
US20150030576A1 (en) | 2012-01-10 | 2015-01-29 | Moderna Therapeutics, Inc. | Methods and compositions for targeting agents into and across the blood-brain barrier |
WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
EP2817322B1 (en) | 2012-02-20 | 2016-04-20 | Universita' degli Studi di Milano | Homo- and heterodimeric smac mimetic compounds as apoptosis inducers |
JP6295512B2 (ja) * | 2012-03-15 | 2018-03-20 | 株式会社豊田中央研究所 | 酵母における外来遺伝子の発現産物の生産方法、酵母における発現調節剤及びその利用 |
AU2013242403B2 (en) * | 2012-03-27 | 2018-10-18 | Curevac Ag | Artificial nucleic acid molecules |
CN108929880A (zh) * | 2012-03-27 | 2018-12-04 | 库瑞瓦格股份公司 | 包含5′toputr的人工核酸分子 |
ES2654205T3 (es) * | 2012-03-27 | 2018-02-12 | Curevac Ag | Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos |
US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
EP2833920A2 (en) | 2012-04-02 | 2015-02-11 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
CN104662171B (zh) | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
WO2014028295A2 (en) | 2012-08-17 | 2014-02-20 | Dow Agrosciences Llc | Use of a maize untranslated region for transgene expression in plants |
WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
WO2014071219A1 (en) | 2012-11-01 | 2014-05-08 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2014184684A2 (en) * | 2013-05-16 | 2014-11-20 | Oslo Universitetssykehus Hf | Methods and biomarkers for detection of hematological cancers |
RU2535871C1 (ru) * | 2013-07-10 | 2014-12-20 | Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") | Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом |
WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015038892A1 (en) | 2013-09-13 | 2015-03-19 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
US9950065B2 (en) | 2013-09-26 | 2018-04-24 | Biontech Rna Pharmaceuticals Gmbh | Particles comprising a shell with RNA |
EP3052479A4 (en) | 2013-10-02 | 2017-10-25 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
US20170173128A1 (en) | 2013-12-06 | 2017-06-22 | Moderna TX, Inc. | Targeted adaptive vaccines |
EP3053585A1 (en) | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
WO2015101415A1 (en) * | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
BR112016014462A2 (pt) * | 2013-12-30 | 2017-10-24 | Curevac Ag | moléculas de ácido nucleico artificiais |
US20170007776A1 (en) | 2014-02-05 | 2017-01-12 | Biontech Ag | Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
US9890365B2 (en) | 2014-03-09 | 2018-02-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
SG11201608798YA (en) | 2014-04-23 | 2016-11-29 | Modernatx Inc | Nucleic acid vaccines |
WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
WO2016005004A1 (en) * | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
EP3708668B1 (en) * | 2014-12-12 | 2022-07-27 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
-
2015
- 2015-10-07 WO PCT/EP2015/073180 patent/WO2017059902A1/en active Application Filing
-
2016
- 2016-10-05 PT PT167787845T patent/PT3337902T/pt unknown
- 2016-10-05 KR KR1020227004459A patent/KR20220025195A/ko not_active Application Discontinuation
- 2016-10-05 RS RS20210311A patent/RS61684B1/sr unknown
- 2016-10-05 CA CA3223575A patent/CA3223575A1/en active Pending
- 2016-10-05 CA CA2998554A patent/CA2998554A1/en active Pending
- 2016-10-05 WO PCT/EP2016/073814 patent/WO2017060314A2/en active Application Filing
- 2016-10-05 LT LT16778784T patent/LT3337902T/lt unknown
- 2016-10-05 EP EP19198322.0A patent/EP3636764B1/en active Active
- 2016-10-05 MX MX2018004160A patent/MX2018004160A/es unknown
- 2016-10-05 HU HUE16778784A patent/HUE046982T2/hu unknown
- 2016-10-05 SI SI201631127T patent/SI3636764T1/sl unknown
- 2016-10-05 PL PL19198322T patent/PL3636764T3/pl unknown
- 2016-10-05 CN CN201680058612.3A patent/CN108291230B/zh active Active
- 2016-10-05 US US15/763,709 patent/US11492628B2/en active Active
- 2016-10-05 NZ NZ740946A patent/NZ740946A/en unknown
- 2016-10-05 DK DK16778784T patent/DK3337902T3/da active
- 2016-10-05 AU AU2016335029A patent/AU2016335029B2/en active Active
- 2016-10-05 ES ES16778784T patent/ES2753201T3/es active Active
- 2016-10-05 KR KR1020187010043A patent/KR102363368B1/ko active IP Right Grant
- 2016-10-05 JP JP2018517549A patent/JP7084302B2/ja active Active
- 2016-10-05 DK DK19198322.0T patent/DK3636764T3/da active
- 2016-10-05 HU HUE19198322A patent/HUE055152T2/hu unknown
- 2016-10-05 RS RS20191347A patent/RS59538B1/sr unknown
- 2016-10-05 BR BR122021025194-0A patent/BR122021025194B1/pt active IP Right Grant
- 2016-10-05 PL PL16778784T patent/PL3337902T3/pl unknown
- 2016-10-05 ES ES19198322T patent/ES2866224T3/es active Active
- 2016-10-05 EP EP16778784.5A patent/EP3337902B1/en active Active
- 2016-10-05 RU RU2018112325A patent/RU2720934C2/ru active
- 2016-10-05 PT PT191983220T patent/PT3636764T/pt unknown
- 2016-10-05 IL IL293020A patent/IL293020A/en unknown
- 2016-10-05 BR BR112018003486-0A patent/BR112018003486B1/pt active IP Right Grant
- 2016-10-05 EP EP21153970.5A patent/EP3868885A1/en active Pending
- 2016-10-05 SG SG10201912558YA patent/SG10201912558YA/en unknown
- 2016-10-05 LT LTEP19198322.0T patent/LT3636764T/lt unknown
- 2016-10-05 SI SI201630441T patent/SI3337902T1/sl unknown
-
2018
- 2018-02-08 ZA ZA2018/00835A patent/ZA201800835B/en unknown
- 2018-03-13 IL IL258074A patent/IL258074B/en unknown
- 2018-04-05 MX MX2021000250A patent/MX2021000250A/es unknown
- 2018-12-07 HK HK18115686.7A patent/HK1256701A1/zh unknown
-
2019
- 2019-01-15 HK HK19100626.1A patent/HK1258262A1/zh unknown
- 2019-10-21 HR HRP20191907TT patent/HRP20191907T1/hr unknown
- 2019-10-23 CY CY20191101105T patent/CY1122347T1/el unknown
-
2020
- 2020-11-16 JP JP2020190088A patent/JP7084565B2/ja active Active
- 2020-11-16 JP JP2020190089A patent/JP6844060B1/ja active Active
-
2021
- 2021-03-17 CY CY20211100230T patent/CY1124066T1/el unknown
- 2021-03-17 HR HRP20210449TT patent/HRP20210449T1/hr unknown
- 2021-04-26 JP JP2021073819A patent/JP7277506B2/ja active Active
- 2021-07-06 IL IL284651A patent/IL284651B/en unknown
- 2021-07-23 AU AU2021206886A patent/AU2021206886B2/en active Active
- 2021-12-01 JP JP2021195628A patent/JP2022050390A/ja active Pending
-
2022
- 2022-09-28 US US17/936,377 patent/US20230272406A1/en active Pending
-
2023
- 2023-12-08 AU AU2023278107A patent/AU2023278107A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3636764T3 (da) | 3'-utr-sekvenser til rna-stabilisering | |
ZA201905396B (en) | Trans-replicating rna | |
IL256905A (en) | Methods for Amplifying Nucleic Acid Sequences | |
DK3445850T3 (da) | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna | |
IL252386A0 (en) | Directed RNA editing | |
DK3319622T3 (da) | Fremgangsmåde til fremstilling af rna-molekylesammensætninger | |
SG11201707663SA (en) | Lyophilization of rna | |
DK3294885T3 (da) | Fremgangsmåde til at fremstille rna | |
DK3351633T3 (da) | Antisense-nukleinsyre | |
DK3436589T3 (da) | Ny minimale utr-sekvenser | |
HK1243712A1 (zh) | 作為用於治療丙型肝炎的hcv抑制劑的核苷酸衍生物 | |
ITUB20153826A1 (it) | Carroponte per costruzioni di strade sopraelevate | |
PT3335729T (pt) | Composição de etanercept com estabilidade melhorada | |
TH1501006377A (th) | การดัดแปลงแบบมีเป้าหมายของจีโนมหนูแรท (targeted modification of rat genome) | |
UA32878S (uk) | Блок скоб | |
TH171939B (th) | สารประกอบอะมิโนไพริมิดิล ซึ่งเป็นสารยับยั้ง jak |